Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01828021 |
Recruitment Status :
Completed
First Posted : April 10, 2013
Results First Posted : September 17, 2020
Last Update Posted : February 10, 2022
|
Sponsor:
MacroGenics
Information provided by (Responsible Party):
MacroGenics
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment |
Condition |
Breast Cancer |
Intervention |
Biological: Margetuximab |
Enrollment | 25 |
Participant Flow
Recruitment Details | Enrollment occurred at 6 US oncology centers -- 4 academic institutions and 2 clinical research centers, between May 2013 and November 2016. |
Pre-assignment Details |
Arm/Group Title | Margetuximab |
---|---|
Arm/Group Description |
Monotherapy of Anti-HER2 monoclonal antibody Margetuximab: Anti-HER2 monoclonal antibody Margetuximab was administered by IV infusion at a dose of 6.0 mg/kg on Days 1, 8, and 15 of each 28-day cycle or or 15 mg/kg every 3 weeks of each 21-day cycle |
Period Title: Overall Study | |
Started | 25 |
Completed | 0 |
Not Completed | 25 |
Reason Not Completed | |
Adverse Event | 5 |
Lack of Efficacy | 17 |
Withdrawal by Subject | 2 |
Ileal obstruction, unrelated | 1 |
Baseline Characteristics
Arm/Group Title | Margetuximab | |
---|---|---|
Arm/Group Description |
Monotherapy of Anti-HER2 monoclonal antibody Margetuximab: Anti-HER2 monoclonal antibody |
|
Overall Number of Baseline Participants | 25 | |
Baseline Analysis Population Description |
All patients who received at least one dose of margetuximab
|
|
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
||
Number Analyzed | 25 participants | |
60.5 (10.08) | ||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 25 participants | |
Female |
25 100.0%
|
|
Male |
0 0.0%
|
|
Race (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 25 participants | |
American Indian or Alaska Native |
0 0.0%
|
|
Asian |
2 8.0%
|
|
Native Hawaiian or Other Pacific Islander |
0 0.0%
|
|
Black or African American |
2 8.0%
|
|
White |
20 80.0%
|
|
More than one race |
0 0.0%
|
|
Unknown or Not Reported |
1 4.0%
|
|
Region of Enrollment
Measure Type: Number Unit of measure: Participants |
||
United States | Number Analyzed | 25 participants |
25 | ||
Eastern Cooperative Oncology Group (ECOG) Performance Status
[1] Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 25 participants | |
Performance Status 0 |
14 56.0%
|
|
Performance Status 1 |
11 44.0%
|
|
[1]
Measure Description: ECOG Performance Status assesses how the disease affects the daily living abilities of the patient and how the disease is progressing or improving. The scale ranges from 0 (fully active, able to carry on all pre-disease performance without restriction) to 5 (dead); therefore, lower numbers indicate better status.
|
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Results Point of Contact
Name/Title: | Chief Medical Officer |
Organization: | MacroGenics, Inc. |
Phone: | 301-251-5172 |
EMail: | info@macrogenics.com |
Responsible Party: | MacroGenics |
ClinicalTrials.gov Identifier: | NCT01828021 |
Other Study ID Numbers: |
CP-MGAH22-02 |
First Submitted: | March 26, 2013 |
First Posted: | April 10, 2013 |
Results First Submitted: | August 13, 2020 |
Results First Posted: | September 17, 2020 |
Last Update Posted: | February 10, 2022 |